Abstract

The adenomatous polyposis coli (APC) gene, known as tumor suppressor gene, has the two promoters 1A and 1B. Researches on APC have usually focused on its loss-of-function variants causing familial adenomatous polyposis. Hypermethylation, however, which is one of the key epigenetic alterations of the APC CpG sequence, is also associated with carcinogenesis in various cancers. Accumulating studies have successively explored the role of APC hypermethylation in gastrointestinal (GI) tumors, such as in esophageal, colorectal, gastric, pancreatic, and hepatic cancer. In sporadic colorectal cancer, the hypermethylation of CpG island in APC is even considered as one of the primary causative factors. In this review, we systematically summarized the distribution of APC gene methylation in various GI tumors, and attempted to provide an improved general understanding of DNA methylation in GI tumors. In addition, we included a robust overview of demethylating agents available for both basic and clinical researches. Finally, we elaborated our findings and perspectives on the overall situation of APC gene methylation in GI tumors, aiming to explore the potential research directions and clinical values.

Highlights

  • The adenomatous polyposis coli (APC) gene is a tumor suppressor gene located in the human chromosome region 5q21–22 [1, 2]

  • The overexpression of DNMT1 was detected in the tissue with hypermethylated APC, which might account for this phenomenon [37]

  • Results of He et al showed that DNA methyltransferase (DNMT) was regulated by transcriptional factor GLI, and APC methylation in pancreatic cancer (PC) might be promoted by DNMT upregulation [72]

Read more

Summary

Frontiers in Oncology

Yang M (2021) APC Promoter Methylation in Gastrointestinal Cancer. The adenomatous polyposis coli (APC) gene, known as tumor suppressor gene, has the two promoters 1A and 1B. Researches on APC have usually focused on its loss-offunction variants causing familial adenomatous polyposis. Hypermethylation, which is one of the key epigenetic alterations of the APC CpG sequence, is associated with carcinogenesis in various cancers. Accumulating studies have successively explored the role of APC hypermethylation in gastrointestinal (GI) tumors, such as in esophageal, colorectal, gastric, pancreatic, and hepatic cancer. The hypermethylation of CpG island in APC is even considered as one of the primary causative factors. We elaborated our findings and perspectives on the overall situation of APC gene methylation in GI tumors, aiming to explore the potential research directions and clinical values

INTRODUCTION
APC METHYLATION IN DIFFERENT GASTROINTESTINAL CANCERS
Esophageal Cancer
Gastric Cancer
Pancreatic cancer
Colorectal Cancer
Liver Cancer
Pancreatic Cancer
Data From Public Databases
DRUG RESISTANCE RELATED TO DNA METHYLATION
APC promoter
POTENTIAL AGENTS EXHIBITING A DEMETHYLATING EFFECT
CONCLUSIONS AND PERSPECTIVES
Findings
AUTHOR CONTRIBUTIONS
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.